Anti-Hu CD262 Purified

Anti-Hu CD262 Purified
Regulatory status
RUO
Antigen
CD262
Clone
DR5-01-1
Format
Purified
Reactivity
Human
Application
Variant
0.1 mg
11-461-C100
In stock
180.00 USD

0.025 mg
11-461-C025
Delivery 1 week
90.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD

0.1 mg
11-261-C100
In stock
90.00 USD
Product details
Description
References
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody DR5-01-1 recognizes an extracellular domain of TRAIL-R2 (DR5). TRAIL-R2 is one of two TNF superfamily members that contain death domain for TRAIL (APO2L).
Workshop
HLDA X
Application
Application details
Flow cytometry: Recommended dilution: 1-4 μg/ml; positive control: JURKAT human peripheral blood leukemia T cell line.
Reactivity
Human
Immunogen
Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
TNFRSF10B, KILLER, TRICK2, TRAIL-R2
Antigen description
TRAIL-R2 (CD262, DR5) is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L). Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.
Entrez Gene ID 8795
UniProt ID O14763

General references:

Corallini F, Milani D, Nicolin V, Secchiero P: TRAIL, caspases and maturation of normal and leukemic myeloid precursors. Leuk Lymphoma. 2006 Aug;47(8):1459-68.
PubMed
Variant
0.1 mg
11-461-C100
In stock
180.00 USD

0.025 mg
11-461-C025
Delivery 1 week
90.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD

0.1 mg
11-261-C100
In stock
90.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
200.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
60.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
50.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
105.00 USD